Dendrite Clinical Systems and the Society for Cardiothoracic Surgery in the UK are pleased to announce the SCTS Conference News 2022 newspaper is now available to view/download. The newspaper reports a multitude of presentations from the meeting including the latest and the best information on new technologies and techniques in cardio-thoracic surgery.
Researchers led by the Clinical Research Unit at the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine, Greece, have initiated a randomised control trial (RCT) that will compare minimally invasive extracorporeal circulation (MiECC) with conventional cardiopulmonary bypass (cCPB).
Dendrite Clinical Systems, working in close cooperation with the SCTS and several cardiac centres, has developed a series of ‘Dashboards’ that allow users to access to their unit’s surgical outcomes and compare them to national results in real-time. By uploading their data to the central Dendrite National Cardiac Surgical Registry, individual units or centres can instantly benchmark their results via an on-line database for internal consumption to assist units with their own clinical governance and for auditing purposes.
Dendrite Clinical Systems is delighted to announce the first ever report from New Zealand’s Te Rēhita Mate Ūtaetae - Breast Cancer Foundation National Register. The ground-breaking report, titled, “30,000 voices: Informing a better future for breast cancer in New Zealand,” covers 30,000 patients diagnosed from 2003 to 2019.
The European Society for Organ Transplantation (ESOT) has signed an agreement to develop a series of web-based registries on organ 
An international team of scientists are investigating a possible curious bi-directional relationship between COVID-19 and diabetes. The researchers, who are part of the CoviDiab project, have hypothesised that the SARS-CoV-2 infection maybe be triggering the onset of diabetes, and they have established a global registry to track occurrence of events and are calling for doctors around the world to contribute reports of cases of new-onset diabetes associated with COVID-19.
The CoviDiab registry is utilising Dendrite Clinical Systems’ innovative “Intellect Web” software to collect new cases of diabetes in patients with COVID-19 to understand the extent and the characteristics of the manifestations of diabetes in patients with COVID-19, and the best strategies for the treatment and monitoring of affected patients, during and after the pandemic. Since the CoviDiab registry was launched a small but growing body of evidence suggests a relationship between new-onset diabetes and COVID-19.
“Over the last few months, we’ve seen more cases of patients that had either developed diabetes during the Covid-19 experience, or shortly after that,” Rubino recently told The Guardian. “We are now starting to think the link is probably true – there is an ability of the virus to cause a malfunctioning of sugar metabolism.”
Despite an association between newly diagnosed diabetes and COVID-19, questions remain regarding causation remain.
It is known SARS-Cov-2 binds to ACE-2 receptors, which are expressed in several key metabolic organs and tissues including the pancreatic β-cells, adipose tissue, small intestine, liver and kidney, CoviDiab researchers stated. Therefore, it is plausible that SARS-Cov-2 could cause multiple co-existing alterations of glucose metabolism that can complicate the pathophysiology of pre-existing diabetes or lead to new mechanisms of disease.
The goal of the registry is to establish the extent and phenotype of new-onset diabetes that is defined by hyperglycaemia, confirmed Covid-19, a negative history of diabetes, and a history of a normal glycated haemoglobin level. The registry, which will be expanded to include patients with pre-existing diabetes who present with severe acute metabolic disturbance, may also be used to investigate the epidemiologic features and pathogenesis of Covid-19–related diabetes and to gain clues regarding appropriate care for patients during and after the course of Covid-19.
The researchers indicated they plan to begin a preliminary analysis once the registry reaches 200 case reports.
To read additional news articles reporting on the CoviDiab project, please see:
For more information on the CoviDiab project, please click here
